News | November 16, 2011

Leadless Pacemaker Stimulates Heart With Wireless Transmission of Energy

November 16, 2011 – Cambridge Consultants unveiled how it has collaborated with start-up company EBR Systems to develop the world’s first wireless pacing system. With cardiac stimulation leads considered the weak point in pacemaker systems, the Wireless Cardiac Stimulation system (WiCS) uses a leadless electrode to convert mechanical energy into electrical energy. The energy is wirelessly transmitted from an ultrasonic pulse generator and used to pace the heart as part of cardiac resynchronization therapy (CRT).  

Eliminating the lead in the left side of the heart presents a major breakthrough in pacemaker design. It also brings new hope for more than 2.2 million advanced heart failure patients worldwide, who can benefit from CRT therapy. The new design provides a life-saving option for those patients who do not benefit from CRT therapy, either because of the complexity of the procedure or the limitations of the current technology.

Current CRT pacemakers or defibrillators are implanted in patients with chronic heart failure requiring both the left and right ventricles to be paced. Such devices require the implantation of three leads. One of those involves painstakingly threading a lead through a difficult and complex route: running from the right atrium of the heart and into the coronary sinus—a vasculature structure on the outside surface of the heart—to the left ventricle.

A pacemaker/defibrillator device is connected to the leads, which are used to sense heart activity and deliver electrical stimulation through electrodes at the end of the leads. The electrical stimulation applied to the right and left ventricles synchronizes the heart’s contraction in a way that improves overall cardiac function in heart failure patients. However, added to the difficulty of the procedure itself is the chance of lead failure and infection.   

WiCS overcomes these problems by leveraging advances in energy harvesting microelectronics. A very small leadless electrode is implanted in the desired location within the left side of the heart. In its first generation, WiCS works in conjunction with a conventional pacemaker/defibrillator, sensing the electrical pacing pulse of the pacemaker from the right ventricle. The pulse generator then transmits an ultrasonic pulse to the implanted receiver; the receiver converts the sonic energy into electrical energy to pace the left ventricle in synchronicity with the right.

This reduces the need for the difficult and complicated surgery associated with CRT pacemakers; by pacing inside the left ventricle, it also better mimics the natural activation and mechanical contraction pattern of the heart. 

With hospital resources already stretched, the leadless system significantly reduces the time taken to carry out the complicated implantation procedure. The WiCS procedure is simple and predictable, resulting in streamlined scheduling of operating theaters and cost savings.

Using its knowledge of integrated circuit (IC) design, Cambridge Consultants helped EBR define the system architecture, which could be realized with modern silicon chip technology. Power consumption, size and safety are critical in pacemaker applications, and the team at Cambridge developed advanced low-power circuits to interface with the ultrasonic transducers and heart monitoring sensors.

With reliability critical, coupled with the need for sophisticated signal processing, the company created two state-of-the-art mixed-signal Application-Specific Integrated Circuits. Both devices are managed by an XAP4 processor. During the development, Cambridge created a full system hardware emulator of the final ASIC. This way, the other system elements and software could be designed and fully tested over a year before prototypes were available. This approach dramatically reduced the overall development time and enabled EBR to ensure the system would work as envisaged.  

For more information: www.cambridgeconsultants.com, www.altran.com

Related Content

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init